View CLICK HERE TO REGISTER REGISTER
PROGRAM OVERVIEW

AREXVY is a vaccine indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus in individuals 60 years of age and older, and in individuals 50-59 years of age who are at increased risk for LRTD caused by RSV. Listen to an expert panel share more details about AREXVY and the recently expanded indication, along with the impact of RSV in adults and important considerations for RSV vaccination.

PROGRAM OBJECTIVES
  • Review RSV disease burden and unmet need
  • Discuss the expanded indication for AREXVY in adults 50-59 years of age at increased risk for LRTD caused by RSV
  • Review important considerations for RSV vaccination
INTENDED AUDIENCE

This broadcast is intended for US healthcare professionals.

{REMOTELIVEEVENTS}
Broadcast Schedule

The broadcast will be available at various times throughout the day, depending on your time zone. Reference the chart below for a complete list of broadcast times.

You may participate in any or all webcast sessions.

Available via

  • Webcast
  • Webcast
  • Tablet
  • Mobile

Broadcast Date: Thursday, July 11, 2024

EASTERN CENTRAL MOUNTAIN PACIFIC
12:15 PM 11:15 AM 10:15 AM 9:15 AM
1:15 PM 12:15 PM 11:15 AM 10:15 AM
2:15 PM 1:15 PM 12:15 PM 11:15 AM
3:15 PM 2:15 PM 1:15 PM 12:15 PM

INDICATION

AREXVY is a vaccine indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in:

  • individuals 60 years of age and older;
  • individuals 50 through 59 years of age who are at increased risk for LRTD caused by RSV.
IMPORTANT SAFETY INFORMATION
  • AREXVY is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of AREXVY
  • Appropriate medical treatment must be immediately available to manage potential anaphylactic reactions following administration of AREXVY
  • Syncope (fainting) may occur in association with administration of injectable vaccines, including AREXVY. Procedures should be in place to avoid injury from fainting
  • Immunocompromised persons, including those receiving immunosuppressive therapy, may have a diminished immune response to AREXVY
  • In adults 60 years of age and older, the most commonly reported adverse reactions (≥10%) were injection site pain (60.9%), fatigue (33.6%), myalgia (28.9%), headache (27.2%), and arthralgia (18.1%)
  • In adults 50 through 59 years of age, the most commonly reported adverse reactions (≥10%) were injection site pain (75.8%), fatigue (39.8%), myalgia (35.6%), headache (31.7%), arthralgia (23.4%), erythema (13.2%), and swelling (10.4%)
  • There are no data on the use of AREXVY in pregnant or breastfeeding individuals. AREXVY is not approved for use in persons <50 years of age
  • Vaccination with AREXVY may not result in protection of all vaccine recipients

Please see full Prescribing Information for AREXVY.

You are encouraged to report vaccine adverse events to the US Department of Health and Human Services. Visit www.vaers.hhs.gov to file a report or call ­1-800-822-7967­.

Funded and Developed by

Trademarks are property of their respective owners.